Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasms 1Melanoma 1

Interventions

pembrolizumab 69Nivolumab 57Ipilimumab 36Specimen Handling 32Magnetic Resonance Spectroscopy 25Cyclophosphamide 22Biopsy 18cemiplimab 14fludarabine 13relatlimab 11binimetinib 11Opdualag 11CTLA-4 Antigen 11trametinib 10fludarabine phosphate 10Radiosurgery 10avelumab 9lifileucel 8dabrafenib 8Radiotherapy 8atezolizumab 7aldesleukin 7Paclitaxel 7Blood Specimen Collection 7encorafenib 6X-Rays 6Standard of Care 6Interleukin-2 6Immunoglobulin G 6HhAntag691 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Acetazolamide × Dermatologic × 90 days × Clear all
NCT05470283 2026-04-16

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
21 enrolled
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡